



## Anouck Thienpont

PHD STUDENT WITH A  
BACKGROUND AS  
INDUSTRIAL PHARMACIST

Born on 1st of August 1994,  
Belgian

 Fruithoflaan 100 bus 39,  
2600 Antwerpen-  
Berchem, Belgium

 anouck.ingrid.thienpont@  
vub.be

 @anouck-thienpont

### SUMMARY

---

During my PhD career I want to combine my pharmaceutical knowledge and interest in dermatocosmetology research to become a scientific expert in the *in vitro* genotoxicology and dermatocosmetology.

### SKILLS

---

#### Personality

- Social, engaged and dynamic
- Comfortable to work both independently and as a team member
- Eager to learn
- Strong ownership of own project and ability to take the lead
- Correct, precise and reliable

#### Software

- Proficient use of Microsoft Word, Powerpoint, Excel, Outlook
- R, GraphPad Prism and Adobe Illustrator

#### Language

Dutch: Mother tongue  
English: Fluent  
French: Fluent  
German: Notion

## CURRENT ACTIVITIES

---

### PHD STUDENT

*Research Foundation Flanders (FWO),  
Flanders – Fellowship strategic basic  
research*

Oct 2020 - Present

*In vitro Toxicology and Dermatology, Vrije  
Universiteit Brussel (VUB) - Academic  
Assistant Staff*

Oct 2019 - 2020

- PhD project: "Next Generation Risk Assessment" (NGRA) to assess the genotoxicity of chemical compounds without the use of experimental animals.
- Pre-submission of GENOMARK to EURL ECVAM in collaboration with the VUB and Sciensano
- Write scientific publications and present research results at (inter)national congresses
- Provide teaching assistance in the course "Toxicology and 3R-alternative methods"
- Active partner in the international projects "Twinning towards excellence in alternative methods for toxicity assessment" (TWINALT) and the "Partnership for the Assessment of Risks from Chemicals" (PARC) project
- Support Master students during their thesis
- Member of the Innovation Centre IC-3Rs and the Belgian and European Societies on Environmental Mutagenesis.

## EDUCATION HISTORY

---

### Masters of Pharmaceutical care

2018 - 2019

Katholieke Universiteit Leuven

### Masters of Science in Drug Development

2016 - 2018

Katholieke Universiteit Leuven,  
*Magna cum laude*

## ADDITIONAL EDUCATIONS

---

- Practical and Theoretical Course on Skin models to assess contact allergens as part of the TWINALT project. Milan, Italy (May 10-26, 2022)
- "in Silico Toxicology": application of QSAR models, read-across and the TTC concept, Fraunhofer Institute for Toxicology and Experimental Medicine (virtual) (2020)
- Safety assessment of cosmetics in the EU, VUB, Brussels (2020)
- Basic programming and transcriptomic analysis using R, LSM-VUB, Brussels (2019-2020)
- Intensive course in Dermato-Cosmetic Sciences, VUB, Brussels (2019)

# RESEARCH OUTPUT

## Publications in peer-reviewed journals

[Thienpont A](#), Cho E., Williams A., Meier M.J., Yauk C.L., Rogiers V, Vanhaecke T and Mertens B. (2023). Unlocking the power of transcriptomic biomarkers in qualitative and quantitative genotoxicity assessment of chemicals. (Manuscript in preparation)

[Thienpont A](#), Verhulst S, van Grunsven L, Rogiers V, Vanhaecke T and Mertens B. (2023). Novel prediction models for genotoxicity based on biomarker genes in human HepaRGTM cells. *ALTEX* 40(2)271–286. doi: 10.14573/altex.2206201

Rogiers V, [Thienpont A](#), Delagrangre M, Mertens B and Vanhaecke T. (2022) Validated alternative methods available for human Health and Safety assessment of cosmetic products and their ingredients in the European Union (Book chapter) fifth Edition: Handbook of Cosmetic Science and Technology, CRC Press. ISBN 9780367469979

Sanders J, [Thienpont A](#), Anthonissen R, Vanhaecke T and Mertens B. (2022) Impact of experimental design factors on the potency of genotoxicants in *in vitro* tests. *Mutagenesis*, 37(5-6),248–258. <https://doi.org/10.1093/mutage/geac025>

## Oral presentations

[Thienpont A](#), Cho E., Williams A., Meier M.J., Yauk C.L., Verhulst S., Rogiers V., Vanhaecke T. and Mertens B. The GENOMARK transcriptomic biomarker: a new approach methodology for genotoxicity (Qualitative and quantitative aspects). Will be presented by Thienpont A. at the Joint 3R Symposium 2023. Brussels (Belgium), Sept 19-21th 2023.

[Thienpont A](#), Cho E., Williams A., Meier M.J., Yauk C.L., V. Rogiers V., Vanhaecke T. and Mertens B. The GENOMARK transcriptomic biomarker demonstrates a high predictivity for genotoxic hazards and utility in potency ranking in human HepaRGTM cells. Presented by Thienpont A. at the EEMGS meeting 2023. Malaga, Spain, May 15-18th 2023.

[Thienpont A](#), Verhulst S, van Grunsven L, Rogiers V, Vanhaecke T and Mertens B. The GENOMARK biomarker in human HepaRGTM cells: a new approach methodology for genotoxicity assessment. Presented by Thienpont A. at the SaferWorldByDesign webinar. Online, February 21 2023

[Thienpont A](#), Verhulst S, van Grunsven L, Vanhaecke T, Mertens B and Rogiers V. The GENOMARK biomarker, a promising new approach methodology for genotoxicity testing to de-risk misleading positive chemicals in the cosmetic industry. Presented by Thienpont A. at the 6th International Conference of Cosmetics. Antalya, Turkey, December 1-3 2023

[Thienpont A](#), Verhulst S, van Grunsven L, Rogiers V, Vanhaecke T and Mertens B. The evaluation of genotoxicity by using novel prediction models based on biomarker genes in human HepaRGTM cells. Presented by Thienpont A. at the OpenTox Virtual Conference. Online, September 12-16 2022

Sanders J, [Thienpont A](#), Anthonissen R, Vanhaecke T and Mertens B. Impact of cell type and exposure time on the quantitative outcome of *in vitro* genotoxicity tests. Presented by Sanders J. at the 13th ICEM conference. Ottawa, Canada, August 27- September 1st 2022

[Thienpont A](#), Verhulst S, Sanders J, De Win D, Tarhonska K, Rogiers V, Vanhaecke T, and Mertens B. GENOMARK gene expression data to compare genotoxic potencies: qualitative and quantitative aspects. Presented by Thienpont A. at the 13th ICEM conference. Ottawa, Canada, August 27 – September 1st 2022

[Thienpont A](#), Verhulst S, van Grunsven L, Rogiers V, Vanhaecke T and Mertens B. Development and comparison of novel prediction models for genotoxicity based on biomarker genes in HepaRGTM cells. Presented by Thienpont A. at the ASCCT-ESTIV webinar. Online, May 16th 2022

Rogiers V. and [Thienpont A](#). Potential Endocrine Disruptors in Cosmetic Products – what Brings the Future. Presented by Rogiers V. at The Virtual 6th ERPA Annual Congress on Regulations and Compliance for Cosmetics. Online, 2-3 February 2022

[Thienpont A](#), Verhulst S, van Grunsven L, Rogiers V, Vanhaecke T and Mertens B. Development of a novel genotoxicity prediction model based on biomarker genes in human HepaRGTM cells. Presented by Thienpont A. at the ASCCT meeting. Online, October 2021.

[Thienpont A](#), Verhulst S, van Grunsven L, Rogiers V, Vanhaecke T and Mertens B. A novel prediction model to evaluate genotoxicity based on a gene signature in metabolically competent human HepaRGTM cells. Presented by Thienpont A. at the Eurotox 2021. Online, September 26 – October 1st 2021

## Poster presentations

Thienpont A., Cho E., Williams A., Meier M.J., Yauk C.L., Rogiers V., Vanhaecke T. and Mertens B. **Unlocking the power of transcriptomic biomarkers in qualitative and quantitative genotoxicity assessment of chemicals.** Poster presentation by Thienpont A. at the EUROTOX23 meeting 2023, Ljubljana (Slovenia) (10-13 September 2023).

Demuyneck E., T. Vanhaecke T., Thienpont A., Rogiers V., Winkelman L.M.T., Beltman J.B., Reus A. , Marcon F., Bossa C., Peijnenburg A., Machera K., Nikolopoulou D., Hatzl V., Paparella M., Kohl Y., Narui S., Molerup S., Dusinska M., Runden-Pran E., El Yamani N., Longhin E.M., Svendsen C., Gutleb A., Pennings J., Luijten M., Adam-Guillermin C., Laurent O., Armant O., Pachoulide C., Bouwmeester H., Raitano G., Benfenati E., Wyrzykowska E., Stepnik M., Puzyn T., Audebert M. and Mertens B. **Development of an AOP-based IATA for genotoxicity.** Poster presentation by Demuyneck E. at the EEMGS/SEMA meeting 2023, Malaga (Spain).

Sanders J, Thienpont A., Anthonissen R, Vanhaecke T and Mertens B. **Impact of experimental design factors on in vitro genotoxicity test results.** Poster presentation by J. Sanders at the IC-3Rs meeting 2022, Brussels (Belgium).

Van Bossuyt M, Hendriks G, Derr R, Doktorova TY, Thienpont A., Van Hoeck E, Vanhaecke T, Rogiers V and Mertens B. **Combining a transcriptomics-based gene expression biomarker with the ToxTracker to evaluate the genotoxic potential of high priority printed paper and board food contact material substances.** Poster presentation by B. Mertens at the Beltox meeting 2019, Brussels (Belgium), November 2019

## Supervisor of Master theses

**Quantitative analysis of genotoxicity data in human Heparg™ cells to support AOP development.** By Seren Sen in order to obtain her Master in Pharmaceutical Sciences at the VUB (2023).

**Potency comparison of aflatoxin B1 and ethyl methanesulfonate in different in vitro genotoxicity tests.** By Julie Sanders in order to obtain her Master in Pharmaceutical Sciences at the VUB (2021).

**Comparative study on the performance of a genotoxin-specific transcriptomics-based gene expression biomarker and traditional genotoxicity tests.** By Femke Daenekindt in order to obtain her Master in Biomedical Sciences at the UA (2020).

## Awards

EPAA 3Rs Student grant to participate in the EUROTOX 23 meeting, obtained on behalf of the EPAA Steering Committee on June 30th, 2023

Travel grant to attend the ICEM meeting, obtained on behalf of the doctoral school of the VUB on June, 6th, 2022

Travel grant to attend the ICEM meeting, obtained on behalf of the Belgian EMS (BEMS) association on May 3rd, 2022

Health and Environmental Sciences Institute (HESI) Genetic Toxicology Technical Committee (GTTC) Professional Development Award, obtained on behalf of the GTTC Education Outreach Committee on April 15, 2022

Ray Tice Tox21 Student Award, obtained at the 10th Annual ASCCT meeting: Practical Applications Of New Tools In Toxicology. Online, October 2021

# EXPERIENCE

---

Short research stay abroad at The Genomics in Regulatory and Applied Toxicology Laboratory, University of Ottawa, Canada. Under supervision of Prof. Dr. C. Yauk. September 5-16, 2022.

- Performed the TempO-Seq technique on 192 HepaRG™ cell lysates
- Participated in the labmeetings
- Collaborated with the bioinformaticians of Health Canada for data analysis of the gene expression data.